Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 13:17:3801-3813.
doi: 10.2147/JIR.S464838. eCollection 2024.

Acute Lung Injury and the NLRP3 Inflammasome

Affiliations
Review

Acute Lung Injury and the NLRP3 Inflammasome

Wanjun Gu et al. J Inflamm Res. .

Abstract

Acute lung injury (ALI) manifests through harm to the capillary endothelium and alveolar epithelial cells, arising from a multitude of factors, leading to scattered interstitial alterations, pulmonary edema, and subsequent acute hypoxic respiratory insufficiency. Acute lung injury (ALI), along with its more serious counterpart, acute respiratory distress syndrome (ARDS), carry a fatality rate that hovers around 30-40%. Its principal pathological characteristic lies in the unchecked inflammatory reaction. Currently, the main strategies for treating ALI are alleviation of inflammation and prevention of respiratory failure. Concerning the etiology of ALI, NLRP3 Inflammasome is essential to the body's innate immune response. The composition of this inflammasome complex includes NLRP3, the pyroptosis mediator ASC, and pro-caspase-1. Recent research has reported that the inflammatory response centered on NLRP3 inflammasomes plays a key part in inflammation in ALI, and may hence be a prospective candidate for therapeutic intervention. In the review, we present an overview of the ailment characteristics of acute lung injury along with the constitution and operation of the NLRP3 inflammasome within this framework. We also explore therapeutic strategies targeting the NLRP3 inflammasome to combat acute lung injury.

Keywords: IL-18; IL-1β; NLRP3 inflammasome; acute lung injury; caspase-1.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Signaling pathways implicated in acute lung injury. (A) AMPK - Nrf2 - HO-1; (B) Wnt - β-catenin - TNF-β; (C) RhoA - ROCK – eNOS; (D) JAK - STAT - IL-6, IL-1β, TNF-α; (E) NF-kB - NLRP3 - caspase-1 - IL-1β, IL-18; (F) VEGF - VEGFR2; (G) PI3K - Akt - mTOR - HIF-1α; (H) MAPKs - JNK - NETs; MAPKs - ERK1/2 - NETs; MAPKs - P38.
Figure 2
Figure 2
Mechanisms of NLRP3 inflammasome activation. The activation of NLRP3 inflammasome occurs via four classical pathways: (1) ion channels; (2) excessive production of reactive oxygen species; (3) mitochondrial autophagy, and (4) lysosomal rupture. Activation of the NLRP3 inflammasome occurs in two phases. In the priming phase, a stimulus binds to pattern recognition receptors and activates NF-kB to further upregulate the expression of NLRP3, pro-IL-1β, and pro-IL-18. In the activation phase, the structural protein NLRP3 binds to the PYD of ASC through oligomerization, whereafter the CARD of ASC binds to the CARC of pro-caspase-1 to form the intact NLRP3 inflammasome. The NLRP3 inflammasome then activates pro-caspase-1, which in turn promotes the maturation of IL-1β and IL-18, in addition to cleaving Gasdermin-D to N- and C-terminal fragments, with the activated N terminus promoting pyroptosis.

Similar articles

Cited by

References

    1. Mowery NT, Terzian WTH, Nelson AC. Acute lung injury. Curr Prob Surg. 2020;57(5):100777. doi:10.1016/j.cpsurg.2020.100777 - DOI - PubMed
    1. Lu Q, Yu S, Meng X, et al. MicroRNAs: important regulatory molecules in acute lung injury/acute respiratory distress syndrome. IJMS. 2022;23(10):5545. doi:10.3390/ijms23105545 - DOI - PMC - PubMed
    1. Mokra D. Acute lung injury – from pathophysiology to treatment. Physiol Res. 2020;69(Suppl 3):S353–S366. doi:10.33549/physiolres.934602 - DOI - PMC - PubMed
    1. Liu C, Xiao K, Xie L. Advances in the use of exosomes for the treatment of ALI/ARDS. Front Immunol. 2022;13:971189. doi:10.3389/fimmu.2022.971189 - DOI - PMC - PubMed
    1. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. IJMS. 2019;20(13):3328. doi:10.3390/ijms20133328 - DOI - PMC - PubMed